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Teaser: Modifying delivery systems with targeting moieties is a relatively recent and 
exciting field which could enhance therapeutics for Parkinson’s disease in the future.  
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Abstract: 
Disease-modifying therapies for Parkinson’s disease – with the potential to halt the 
neurodegenerative process and to stimulate the protection, repair and regeneration of 
dopaminergic neurons – remain a vital but unmet clinical need. Therapeutic targeting 
offers the potential for delivery of neuroprotective and disease-modifying molecules to 
the diseased brain region. This relatively new field of research has many opportunities – 
but also many challenges – for improving the quality, specificity and efficacy of the next 
generation of therapies for Parkinson’s disease patients in the future. 
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Age-related neurodegenerative diseases are a group of conditions that affect patient 
motor and/or mental independence, and lead to a general lowering of quality of life. After 
Alzheimer's disease, Parkinson's disease (PD) is the second most prevalent of these 
neurological disorders, with an incidence of 8.6 to 19.0 per 100,000 inhabitants [1]. PD 
was first described by the English doctor, James Parkinson, in his 1817 essay "An 
Essay on the Shaking Palsy" [2], and it has since been further characterised by a 
progressive loss of midbrain dopaminergic neurons as well as the presence of α-
synuclein protein aggregates forming intracellular Lewy bodies in affected areas. First 
introduced over half a century ago [3], replacement of the neurotransmitter dopamine 
with the precursor levodopa (L-DOPA) remains the backbone therapeutic for standard 
PD therapy. However, L-DOPA (as well as all other pharmacological therapies for PD) is 
limited in that it only treats the motor symptoms of the disease, it does not alter the 
relentless degeneration of the affected neurons as the disease progresses, and it is 
associated with significant side effects in advanced disease. Therefore, it is imperative 
that novel disease-modifying therapies that have the potential to halt the 
neurodegenerative process itself, and to stimulate the protection, repair and 
regeneration of dopaminergic neurons, are developed sooner rather than later.   
When considering the hurdle of designing new targeted therapeutic interventions for PD, 
it is interesting to place the challenge into context with other neurodegenerative 
diseases. In comparison to other such diseases, PD offers both specific challenges as 
well as specific opportunities for targeted therapies. One of the challenges is that, unlike 
Huntington's disease (which is caused by mutations in one specific gene), the cause of 
sporadic PD (which accounts for the vast majority of cases) remains unknown. Having 
said that, in recent years, linkage analysis and genome-wide association studies have 
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revealed a potential genetic basis for at least some cases of “sporadic” PD [4,5]. One of 
the opportunities afforded by the nature of the PD pathology is that it is primarily 
restricted to a specific location within the brain (namely the nigrostriatal pathway) which 
is undoubtedly less of a challenge for targeting therapies than the widespread areas 
affected in many other neurodegenerative conditions, such as multiple sclerosis or 
Alzheimer's disease. Moreover, as PD results in the relatively specific loss of 
dopaminergic neurons, there is also a specific population of target neurons for 
neuroprotection and replacement, in contrast to most other neurodegenerative 
conditions with diverse patterns of cell loss, such as traumatic brain injury or stroke. The 
long time period over which the disease progresses also presents both challenges and 
opportunities. Unlike amyotrophic lateral sclerosis, which typically progresses rapidly 
over three years or so, the disability of PD is typically extended over 2 decades or more. 
This gives a window-of-opportunity suitable for therapeutic intervention and, perhaps in 
the future, for "personalized medicine" approaches. However, this advantage is at least 
in part offset by the relative plasticity of dopaminergic neurons to compensate for partial 
loss, such that symptoms are not observed and hence diagnosis delayed until brainstem 
dopaminergic cell loss exceeds 70% or more [6]. 
Certain growth factors, such as glial cell line-derived neurotrophic factor (GDNF), show 
strong promise for protecting the remaining dopaminergic neurons in PD patients. 
However, the long time scale of PD progression also presents a challenge for growth 
factor therapies, which, due to the short protein half-life will require sophisticated 
controlled release systems, continual infusion devices or gene therapy interventions. 
Moreover, since large molecules such as growth factors do not readily cross the blood-
brain barrier, these requiring targeted, typically surgical, central delivery to the required 
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site of action. Thus, PD has certain features that give firm rationale for the development 
of targeted therapies, and in particular growth factor therapies. To summarise, these 
include the selectivity of neuron loss in a particular brain region, an array of potential 
therapeutic agents, and a suitable time period for neuroprotection. However, challenges 
include the unknown etiology, patient–to-patient variability in Parkinsonian pathology 
and symptoms, and the length of time over which the therapy needs to remain active to 
be effective.  
Route to the Target Area 
When designing a targeted therapy for any disease, it is essential to consider by which 
means it is expected to reach the target site. The majority of current PD drugs are 
administered orally which results in system-wide distribution via the bloodstream despite 
an effect being desired in the nigrostriatal pathway only. The nature of absorption 
through the gastrointestinal track inevitably results in periods of high drug concentration 
in the blood, or a low concentration, depending on when the last administration took 
place. This escalation and reduction in dopamine concentration can later result in an 
“on-off” effect, whereby patient mobility is severely compromised before the next dose is 
taken. In addition, this rise and fall of drug-derived dopamine levels may cause a 
worsening of motor complications such as involuntary movements (dyskinesias) [7].  
Figure 1 and Table 1 about here 
 
Stereotactic surgery offers an alternative to the blood stream as a route to the 
nigrostriatal dopaminergic pathway. Intraparenchymal administration bypasses the 
blood-brain barrier (selective permeability barrier separating blood flow from the brain 
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extracellular fluid (see Figure 1)) to target sites such as the striatum or substantia nigra 
directly. Alternatively, stereotactic intraventricular injection also bypasses the blood-brain 
barrier, but due to the large volume of the ventricles within the brain, the drug can still 
act upon a large region of the brain (i.e. areas in proximity to the ventricles). As with 
most aspects of drug design, there are advantages and disadvantages to either delivery 
route (systemic vs. stereotactic) which are considered in Table 1. 
The above consideration of the administration route shows that the design of targeted 
therapies for PD alters considerably depending on whether systemic or stereotactic 
administration is envisaged. Therefore, recent developments towards novel therapeutics 
for PD are considered separately below. 
Targeting Delivery with Stereotactic Surgery 
When considering targeted therapies for PD, one strategy might be the development of 
nanoparticles designed to carry payloads across the blood-brain barrier. This is indeed a 
large focus of novel therapeutic research, however stereotactic injection of controlled 
release devices directly into the brain provide another means to directly target the 
ascending dopamine pathways and their striatal terminals. In addition, intracerebral 
injection can allow for the delivery of larger biomaterial devices such as microspheres, 
which otherwise would not be able to cross the blood brain barrier, directly into host 
neuropil. This section will review recent work involving growth factor and gene delivery 
to the brain, highlighting the materials used and therapeutic molecules delivered. 
Growth factors such as GDNF have been extensively shown to protect dopaminergic 
neurons from toxic insult [8,9], so represent a major promise for future disease-
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modifying PD therapies (i.e. to reduce the death rate of dopaminergic neurons). 
However, as GDNF requires a long time frame of action in order to slow the disease 
progression, some form of continual delivery (e.g. pump) or controlled release (e.g. 
biomaterial or other vectors) system must be considered to overcome the short half-life 
of the protein. A recent review of the different biomaterials used for therapeutic delivery 
to the CNS highlights poly(lactic-co-glycolic acid) (PLGA) as a material which has been 
studied extensively for the delivery of therapeutics [10]. With regulatory approval for use 
in humans and a biodegradation profile that can be tailored easily (via monomer 
composition), PLGA is a good candidate for the preparation of GDNF-loaded micro-
spheres that can be used to deliver sustained neurotrophic factor release in the brain. 
PLGA microspheres can be prepared in emulsion and loaded with GDNF. Using the 6-
hydroxydopamine (6-OHDA) model of PD, the neuroprotective property of GDNF-loaded 
microspheres injected into the striatum can yield an impressive functional motor benefit 
(reversal of amphetamine-induced rotational behaviour) in rats [11,12], lasting up to at 
least 30 weeks [13]. However, care should be taken when extrapolating these results to 
the human condition. The 6-OHDA model is an acute toxic model which selectively 
destroys the midbrain dopaminergic neurons, but does not simulate the slow progressive 
nature of PD. Whilst GDNF release can be observed over a period of days or weeks 
[11], the design of materials for constant release over months and years remains a 
formidable task.  
Gene therapy could be an alternative means of maintaining an elevated level of striatal 
GDNF over a sustained period. A general outline for successful gene therapy for PD 
involves using a vector capable of delivering a gene encoding the neurotrophic factor to 
cells in the nigrostriatal pathway in order to allow the transfected/transduced cells to 
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secrete the neurotrophic factor. To date, the most effective vectors remain viral vectors, 
despite much research into developing non-viral alternatives. For example, lentiviral-
mediated GDNF overexpression has impressively been shown to ameliorate the effects 
of a 6-OHDA lesion, including behaviour benefits in a wide range of behavioural tasks 
[14]. Indeed, adeno-associated virus (AAV)-mediated gene delivery has reached clinical 
trials for the delivery of the growth factor GDNF-analogue, neurturin, to patients with 
relatively advanced PD [15].  
Non-viral vector counterparts lag behind, both in terms of transfection efficiency in the 
brain [16] and clinical development, and this has been reviewed extensively elsewhere 
[17]. However, polymer-based non-viral vectors offer the potential for systemic 
administration (see below), repeat administrations, addition of targeting ligands, and 
feasible up-scale/ease of handling. The addition of targeting ligands (sometimes termed 
‘moieties’) to non-viral vectors is not limited to those proposed for systemic 
administration. Specific targeting of gene therapy to neurons has been attempted using 
the Tet1 peptide attached to a polymeric vector. Intraventricular delivery resulted in the 
specific transfection of neural progenitor cells in the sub-ventricular zone [18]. A 
targeting peptide has also been used to specifically target the neurotensin receptor of 
dopaminergic neurons [19]. The neurotensin peptide sequence has been added to a 
poly-L-lysine gene vector in order to deliver the GDNF encoding gene to the 6-OHDA rat 
model of PD [20]. Intranigral administration of the neurotensin modified gene vector 
resulted in robust protection of the dying neurons, both in the substantia nigra and in the 
striatum. Such studies mark how non-viral gene transfection has progressed from 
standard cationic polymers [21] to peptide modified vectors capable of bringing about 
functional recovery in a rodent model of PD. However, if the design of non-viral gene 
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vectors is restricted to the stereotactic route of administration, they will either have to 
become as efficient as viral vectors, be proven safer, and/or become cheaper to 
produce/handle than their viral counterparts. The development of non-viral vectors which 
can target the brain, by using bound ligands to mediate their transfer across the blood 
brain barrier, opens up the possibility of systemic administration for future nanomedicine 
therapies for PD. This line of research could provide significant advantages over viral 
gene delivery, and drug/gene carriers and their respective targeting ligands are 
discussed below.  
Targeting Delivery with Systemic Administration 
The development of biomaterials to improve drug delivery for PD has focused heavily on 
sustained delivery of L-dopa in a non site-specific manner (reviewed elsewhere [10]). 
However, drug delivery systems designed to translocate small molecule drugs across 
the blood brain barrier have also been developed. In 1984, a key study showed that if 
monoclonal antibodies (mAb) against transferrin (Tf) receptors were systemically 
administered to the rat, they labelled the capillaries in the brain, but not other tissues 
[22]. Researchers have now extensively investigated the use of targeting ligands such 
as mAb against Tf receptors, the Tf glycoprotein itself, or glycoproteins from the 
transferrin family (e.g. Lactoferrin) for translocation of nanomedicines across the blood 
brain barrier. Whilst many of the recent studies have been focused on non-viral gene 
vectors, lactoferrin has also been conjugated to PLGA nanoparticles containing urocortin 
[23]. Urocortin is a corticotrophin releasing hormone which was shown to be 
neuroprotective in the rat 6-OHDA and lipopolysaccharide (LPS) models of PD [24] after 
intranigral injection. Since urocortin cannot transverse the blood brain barrier, Hu and 
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co-workers used PLGA nanoparticles, modified with lactoferrin via a polyethylene glycol 
(PEG) spacer, to successfully deliver urocortin to the brain following systemic 
administration in the Parkinsonian mouse [23]. Lactoferrin has also been used as a 
brain-targeting ligand for cationic polymers designed for gene delivery. 
Poly(amidoamide) (PAMAM) dendrimers, functionalized with lactoferrin or transferrin, 
again by a PEG spacer, allowed the delivery of the GDNF encoding gene to the brain of 
rodent PD models [25,26]. Lactoferrin modified PAMAM showed greater GDNF 
expression levels in the brain, than transferrin modified PAMAM, so was used for further 
study into a multiple dosing regime in the rotenone rat model of PD [25]. Five injections 
resulted in higher GDNF expression levels than three injections (Figure 2), but 
behavioural improvement was similar between these groups, as was the density of 
tyrosine hydroxylase (TH) immunopositive staining (dopaminergic terminals) in the 
striatum. Studies such as these prove the concept that non-viral gene delivery can be 
achieved in the rodent brain, and that multiple dosing can be used. However, we must 
also not overlook the short duration of transgene expression, as can be observed in the 
progressive reduction of expression in the 2, 6 and 10 day analyses (Figure 2).  
Figure 2 about here 
 
Aside from lactoferrin, other targeting moieties have been used for nanoparticle delivery 
to the brain (reviewed elsewhere [27]). Some examples include angiopep, a ligand which 
specifically binds to the low-density lipoprotein receptor-related protein present on the 
blood brain barrier [28], and the rabies virus glycoprotein peptide, a 29 amino-acid 
peptide which binds to the nicotinic acetylcholine receptor which is widely expressed in 
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the brain and blood brain barrier [29]. There are few direct comparisons between the 
many different brain targeting moieties, however, van Rooy and colleages [30] used 
liposomes as the vector and varied the targeting functionality. This study showed that 
RI7217, a monoclonal antibody against the mouse transferrin receptor was preferable to 
the antibody OX-26, transferrin itself, angiopep, and other moieties designed to cross 
the blood brain barrier [30]. This study can also serve to highlight the current limitation of 
systemic delivery to the brain, namely the problem of off-target accumulation. 
Incremental improvements in brain uptake are achieved via correct selection of targeting 
ligands (Figure 3B), however, the degree of off-target accumulation is considerably 
larger, particularly in the liver and spleen (Figure 3A) [30]. This is a common observation 
in studies where delivery from the blood stream to the brain is desired, and a hurdle 
which must be overcome for further progress in this field.  
Figure 3 about here 
 
These studies have focused primarily on targeting the brain in general; however, PD 
affects a specific brain region and a specific type of cell. When designing therapies 
specifically targeted at the regions affected by PD, gene therapies hold an advantage in 
that they can contain two means of targeting the transgene effect. The first is the 
targeting ligand present on the polymer/nanoparticle/liposome etc., as mentioned above. 
The second is that a region specific promoter might be used, so that transgene 
expression would only be driven in the desired region or specific population of cells, for 
example in TH-positive catecholaminergic neurons. TH-specific expression of GDNF has 
been successfully achieved in rodent PD models using PEGylated liposomes known as 
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“Trojan Horse Liposomes” [31,32]. These liposomes are functionalized with the mouse 
transferrin receptor monoclonal antibody OX-26 to assist crossing the blood brain 
barrier, and the GDNF encoding gene contains a TH-specific promoter instead of a more 
widely expressed promotor. Together, such systems allow an acceptable level of brain 
uptake, yet may provide a means of circumventing the problem of off-target 
accumulation of the therapeutic. 
Could Cell Therapies be Better Targeted? 
As highlighted in the previous sections, designing targeting strategies for better delivery 
of drugs, growth factors and genes to the brain is a relatively recent research area but is 
of growing interest. An alternative possibility is the use of cell transplantation to deliver 
targeted cells or therapeutic molecules on a sustainable basis into the Parkinsonian 
brain. Cell therapies are being considered as a potential means to replace the neurons 
lost in PD [33,34] or as a means of providing neurotrophic support [35]. Supportive 
biomaterials are being considered to improve transplant survival [10,17], but they can 
also provide a means of better stabilisation and positioning of the graft within the target 
area (e.g. striatum; see figure 4). Striatal placement of cell transplants do not always 
result in all of the cells remaining in the striatum after the needle is withdrawn. In the 
authors’ experience, grafted cells can frequently be observed in the corpus callosum 
and/or in the overlying cortex, whether through inadvertent deposition at the time of 
injection, pressure extrusion as the needle is withdrawn, or by graft expansion and 
growth in the weeks subsequent to transplantation surgery (for examples see figure 4 
and reference [36]). Hydrogels which form in situ, i.e. in the brain post-injection, such as 
those formed from collagen used previously for delivery of stem cells to the brain [37], 
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have the potential to form a means of retaining the grafted cells in a single transplant 
site. Alternatively, biomaterial spheres or scaffolds have been used to deliver GDNF to 
promote engraftment by improving graft integration in the brain [38,39]. Moreover, when 
fetal ventral mesencephalon cells were pre-adhered to PLGA spheres, the survival was 
improved [40], showing that perhaps materials designed to be cell adherent could serve 
a dual purpose of holding the graft in a specific position and improving survival. One 
problem of such strategies is that such materials result in a “dead space” in the brain, 
during the material degradation time, and the scaffold size is limited to the small injection 
cannula diameter. To overcome these problems, we are currently developing highly 
macroporous microscale cryogel particles to which neurons can adhere, but, in a 
manner similar to a sponge, they can collapse to fit through a needle, and re-expand to 
the original shape if volume allows [41].  
Figure 4 about here 
 
The majority of transplantation studies in the parkinsonian animal brain use intra-striatal 
injection because nigral grafts fail to project as far as the striatum, to make relevant re-
connections. However, supportive tracts from the substantia nigra to the striatum have 
been formed either with a stimulatory amino acid (kainic acid), or Schwann cells to 
promote ventral mesencephalic grafts to project from the substantia nigra to the striatum 
[42,43]. Such nigrostriatal “bridges” could be supported by biomaterial scaffolds, such as 
PEG hydrogel rods [44]. To reduce the dead space occupied by such materials, one 
could look to the recent developments in cryogel technology to develop highly porous 
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and shape memory materials, which can be injected and allow neuron growth through 
the scaffold matrix [45,46].  
Conclusion 
The lack of disease modifying strategies for PD provides strong rationale for the delivery 
of neuroprotective growth factors, gene therapies or replacement cells. Targeting the 
delivery begins with the question of systemic or stereotactic administration, and 
depending on which is most desirable for this therapy, a variety of targeting ligands can 
be considered. The problem of off-target accumulation may be easier to circumvent with 
gene therapies by the use of site-specific promoters, whereas growth factor delivery may 
benefit from controlled release devices delivered directly to the target area. Lastly, we 
speculate as to whether biomaterials could be used for better positioning of cells 
transplanted into the nigrostriatal pathway. This relatively new field of research has 
many challenges, but also many opportunities, for improving the quality of therapy of PD 
patients in the future.  
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Tables 
Table 1. The advantages and disadvantages of systemic vs. stereotactic drug delivery. 
Systemic Drug Administration  
Disadvantages: Advantages: 
1. Significant barriers to circumvent (see 
Figure. 1) such as opsonisation, removal 
by the reticulo-endothelial system (RES), 
and the blood-brain barrier.  
2. Off-target effects. 
1. Low cost. 
2. Ease of repeat administration. 
3. High patient acceptance. 
 
Stereotactic Drug Administration  
Disadvantages: Advantages: 
1. High cost. 
2. Requires skilled surgeon. 
3. Risk of infection. 
4. Increased risks with repeat 
administrations. 
5. Possibility of low patient acceptance. 
 
1. Bypasses the blood-brain barrier. 
2. Suitable for large cargo such as 
protein/cells, or therapeutics 
unsuitable for brain-barrier permeation 
such as viral vectors. 
3. Can target the affected region directly, 
so targeting moieties only need to be 
tailored to specific cell types. 
4. No or reduced off-target effects. 
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Figure Legends 
Figure 1. Schematic depiction of the barriers to targeting systemically administered 
therapies to the brain as opposed to direct stereotactic injection. Many of the barriers to 
effective delivery via systemic administration (such as phagocytosis, removal by the 
reticulo-endothelial system (RES), degradation and crossing the blood brain barrier) can 
be overcome by stereotactic injection. However, the advantages and disadvantages of 
both routes are discussed further below. 
Figure 2. GDNF expression levels in the rat brain after systemic gene therapy. Top 
panel (A) shows the effect of various modifications made to the PAMAM vector (NP) on 
transgene efficiency, with poly(ethylene glycol)(PEG), Transferrin (Tf) and Lactoferrin 
(Lf) all improving the GDNF expression in the brain as detected by ELISA. Lower panel 
(B) shows GDNF expression: (1) two days post single saline injection; (2) two days post 
single Lf-modified NP injection; (3) six days post single Lf-modified NP injection; 
(4) ten days post single Lf-modified NP injection; (5) two days post triple injections of Lf-
modified NPs, one injection every other day; (6) two days post five injections of Lf-
modified NPs, one injection every other day. This study shows the short transgene 
expression window, but also the additive effect of repeat administrations (5 and 6). 
Image reproduced with permission from [25].  
Figure 3. Accumulation of liposomes with different targeting proteins/peptides, 
reproduced here with permission from [30], to highlight the high level of off-target 
accumulation in mice (in particular the liver) as opposed to the cerebellum/cerebrum.  
Figure 4. A schematic diagram modified from [10], to show a side view of the substantia 
nigra, striatum, and surrounding ventricles (in grey). A typical needle tract is shown and 
potential regions for off-target therapeutic delivery are shown in red. The insert shows an 
image reproduced with permission from [36], showing a graft residing in the rat striatum 
as desired (left) and a graft with a large percentage in the cortex (right), representing the 
possibilities for improving graft positioning within the brain. 
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Figure 1. 
 
Figure 2. 
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Figure 3. 
 
Figure 4. 
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